Multiple Sclerosis Therapeutics Market in Europe Is Driven By High Prevalence of Multiple Sclerosis in the Region

 

Multiple Sclerosis Therapeutics Market

Multiple sclerosis is a long-term disease that attacks the central nervous system, affecting the brain, spinal cord, and optic nerves. It can lead to a wide range of symptoms throughout the body. There are four types of multiple sclerosis: clinically isolated syndrome, relapse-remitting multiple sclerosis, primary progressive multiple sclerosis, and secondary progressive multiple sclerosis. Around 80 percent of people with multiple sclerosis report having fatigue. Other symptoms include, acute or chronic pain, tremor, and cognitive issues involving concentration, memory, and word-finding difficulty. Although there is not yet a cure for multiple sclerosis, there are many effective medications to help you manage the disease.

According to a study by National MS Society, published in February 2019, in the journal Neurology, in 2017, nearly 1 million adults were living with multiple sclerosis in the U.S. Such high prevalence is expected to aid in growth of the multiple sclerosis therapeutics market.

Treatment for multiple sclerosis may include, chemotherapy, anti-inflammatory drugs, monoclonal antibodies, immunosuppressive drugs, and steroids. In September 2019, F. Hoffmann-La Roche Ltd., a major player in the multiple sclerosis therapeutics market, presented OCREVUS (ocrelizumab) biomarker data that highlights new insights into the biology of multiple sclerosis at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden.

The multiple sclerosis therapeutics market in Europe is driven by high prevalence of multiple sclerosis in the region. According to data from (updated November 2018), the Multiple Sclerosis Trust, the prevalence of MS in England is around 90,500 or 164 per 100,000 and about 3,200 or 175 per 100,000 in Northern Ireland.

Multiple sclerosis treatment is often used to slow the progression of the disease and relieve symptoms. Currently, there are various approved drugs to treat multiple sclerosis in the multiple sclerosis therapeutics market that include, Fingolimod (Gilenya), Dimethyl fumarate (Tecfidera), Diroximel fumarate (Vumerity), Teriflunomide (Aubagio), Siponimod (Mayzent), and Cladribine (Mavenclad). IV steroids are sometimes used to reduce and control the symptoms of an acute attack of multiple sclerosis. Players in the multiple sclerosis therapeutics market can also focus on autologous hematopoietic stem cell transplant as a potential option. In November 2020, the National MS Society stated that autologous hematopoietic stem cell transplant represents “a useful treatment option” for patients with relapsing multiple sclerosis who experience breakthrough disease activity despite disease-modifying therapy.

Comments

Post a Comment

Popular posts from this blog

Astrum Has Expanded Its Presence In India Infrared Thermometer Market

Image
  The Infrared Thermometer market is witnessing the fastest growth in the Asia Pacific region and this can be accredited to the growing aging population in the region which is driving demand for healthcare services. Japan has the highest growing aging population in the country. According to the Statistics Bureau, Ministry of Internal Affairs and Communications, in 2019, the aged population (65 years old and over) was 35.89 million, constituting 28.4 percent of the total population (i.e., 1 in every 4 persons) and marking a record high in Japan. The rise in prevalence of infectious disease and increase in the demand for the product for newborns as children cannot hold the contact thermometer is playing a key role in the overall development of the infrared thermometer market . According to the World Health Organization, HIV, tuberculosis, malaria, neglected tropical diseases, and viral hepatitis affects billions of people around the world and causes more than 4 million deaths each year
Read more

The Global Meningococcal Vaccines Market Continues To Grow Owing To the Demand from Healthcare Care Sectors across the World to Prevent the Spread of the Diseases Especially In Children

Image
  Meningococcal vaccines prevent the contraction of meningococcal diseases, including meningitis caused by the bacteria called meningococcus aureus. An outbreak of meningococcal disease is usually followed by an onset of meningitis. Meningococcal meningitis can cause permanent damage to the brain or spinal cord in as little as 10 days, depending on the degree of infection and the natural immunity of the person. Since meningitis is usually associated with a fever and signs and symptoms of a serious illness, many parents prefer not to use the traditional treatments for their children such as meningitis or oral antibiotics. Instead, they often resort to various forms of therapeutic interventions that may even improve their chances of developing a positive outcome. Meningococcal vaccines are now available for meningococcal meningitis, as well as for men who have had other prior bouts of meningitis. Some vaccines used for these purposes are PPSV, Rallo, and Q fever type 1. These vaccines
Read more

Increasing Geriatric Population Is Driving the Growth of the Sexual Health Market

Image
       Sexual health is an important part of a person’s physical and mental health. According to the World Health Organization (WHO), sexual health requires a respectful and positive approach to sexual relationships and sexuality, as well as the possibility of having pleasurable and safe sexual experiences, free of coercion, violence, and discrimination. Sexual health leads to a healthy sex life without any sexually transmitted diseases, and to take preventive measures to avoid sexually transmitted infections. The elderly population (geriatric population) often suffer from one or more sexual disorders, such as premature (early) ejaculation, erectile dysfunctions, dyspareunia, and hypoactive sexual desire disorder, among others. Thus, with the increasing geriatric population worldwide, the prevalence/incidence of sexual disorders is also increasing, driving the growth of the sexual health market . According to WHO, the world's population aged 60 years and older is expected to tota
Read more